An announcement from Conavi Medical ( (TSE:CNVI) ) is now available.
Conavi Medical Corp. has successfully closed a $20 million public offering to fund the development and pre-clinical testing of its Novasight 3.0 technology, with plans to seek FDA clearance later in 2025. This financial boost is expected to enhance the company’s operational capabilities and strengthen its market position in the cardiovascular imaging sector, with significant implications for stakeholders, including insider investors who participated in the offering.
More about Conavi Medical
Conavi Medical is a commercial stage medical device company that specializes in designing, manufacturing, and marketing imaging technologies for minimally invasive cardiovascular procedures. Its flagship product, the Novasight Hybrid System, uniquely combines intravascular ultrasound and optical coherence tomography for coronary artery imaging, and has received regulatory approvals in multiple countries including the U.S., Canada, China, and Japan.
YTD Price Performance: -33.33%
Average Trading Volume: 4,586
Technical Sentiment Signal: Strong Buy
Current Market Cap: $4.92M
For an in-depth examination of CNVI stock, go to TipRanks’ Stock Analysis page.